Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 Open-label Study of BLB-750 H5N1 Influenza Vaccine in Healthy Japanese Adults
jRCT1080223741Phase 4Completed
- Sponsor
- Takeda
- Start
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of BLB-750 in Influenza A H5N1 infection (H5N1), sponsored by Takeda. Primary endpoints: Immunogenicity of BLB-750 and Safety and tolerability of BLB-750. Started Dec 2017; status: completed.
02
Drugs
BLB-750
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on jRCT1080223741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223741.